Roivant reported fourth-quarter fiscal 2026 revenue of $2.52 million, below analyst estimates, while GAAP earnings per share from continuing operations was $0.43, significantly beating expectations due to a large, one-time litigation gain.

Key Highlights

  • The quarter's profitability was driven by a one-time pre-tax gain of $770.2 million from a global patent litigation settlement with Moderna.
  • Positive clinical data for IMVT-1402 in difficult-to-treat rheumatoid arthritis showed a 72.7% ACR20 response rate at Week 16.
  • Brepocitinib was granted Breakthrough Therapy Designation by the FDA for the treatment of cutaneous sarcoidosis following positive Phase 2 data.
  • The company ended the fiscal year with cash, cash equivalents, and marketable securities of $4.3 billion, supporting its runway.